The highest ORR was seen in studies also combining cytotoxic chemotherapy: 38.5% in combination with pembrolizumab, 5-fluorouracil, and platinum drugs in treatment-naïve head and neck cancers (DCR 84.6%), and 72.2% in combination with trastuzumab, ramucirumab, and paclitaxel in recurrent HER2+ gastroesophageal cancers (DCR 88.9%) (31). The gene discussed is ERBB2; the disease is head and neck cancer.